Immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4); programmed cell death 1 (PD-1); and PD-1’s main ligand PD-L1, have been introduced for the treatment of more than a dozen types of cancers [18,19,20]. Here, PDCD1 is linked to cancer.